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Key Clinical Message
Pseudomyxoma peritonei is rare. The rarity is highlighted by the lack of pub-
lished evidence regarding management. The latest treatments have altered the
prognosis of a once incurable disease. This report serves to both raise awareness
and critically appraise the literature regarding the latest management.
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Case Presentation
A 75-year-old gentleman was referred to outpatient gas-
troenterology services due to a 3-month history of weight
loss, abdominal pain, and abdominal distension. His past
medical history was significant for atrial fibrillation,
hypertension, bilateral knee replacements, and obstructive
sleep apnoea. On presentation to the outpatient clinic, the
patient appeared cachectic with marked abdominal disten-
sion. The patient denied significant alcohol consumption
and a thorough history ruled out any risk factors for liver
disease. He did, however, admit to increasing lethargy
and malaise. Examination confirmed generalized muscle
wasting; abdominal palpation revealed a huge epigastric
mass and abdominal distension consistent with ascites.
No signs of chronic liver disease were seen.
Differential Diagnosis
The weight loss and ascites point toward a diagnosis of
malignancy, possible disseminated. Isolated right or bi-
ventricular failure remains a possibility especially, given
the associated lethargy. Although unlikely in the absence
of signs of chronic liver disease and compatible history,
decompensated liver disease remains in the differential
diagnosis and was therefore investigated for Other rarer
differentials encompass tuberculosis and sarcoidosis.
In the author’s experience, in a gentleman presenting
with ascites, the “default” diagnosis appears to be decom-
pensated alcoholic liver disease. Such stereotyping is
unacceptable and undoubtedly results in missed diagno-
ses, poor clinical care, and is a source of anxiety and dis-
tress amongst patients. In this patient, a thorough alcohol
consumption history and clinical examination by the
admitting team helped avoid this.
Investigations
Blood investigations were essentially normal apart from a
raised Ca19-9 (208) and CEA (88) levels. An ascitic tap
revealed an almost gelatinous, straw-colored fluid. Cyto-
logical analysis of the fluid revealed the presence of foamy
cytoplasm-containing mesothelial cells with eccentric
nuclei (mucin-containing epithelial cells). A liver screen
was negative.
Computed tomography (CT) of the abdomen revealed
extensive ascites and a large cystic tubular structure mea-
suring 15 9 6 cm, consistent with an appendiceal muco-
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cele (Fig. 1, coronal section). Further, sections of the CT
scan (Sagittal and Transverse) revealed extensive omental
caking in the epigastric region (Figs. 2 and 3).
Outcome and Follow Up
The patient underwent an extensive debulking operation;
histology from peritoneal and adipose tissue revealed dis-
seminated peritoneal adenomucinosis (DPAM). He has
subsequently had heated intraperitoneal chemotherapy
(HIPEC) (mitomycin C), and is in clinical remission.
Literature Review
Pseudomyxoma peritonei (PMP) is a rare diagnosis with
an incidence of 1–2 per million [1]. Coined by Werth in
1884 [2], PMP was initially thought of as a peritoneal
reaction to the “jelly-like” secretions produced by an
ovarian neoplasm [1]. Points of contention as to the exact
origin of this condition, especially in women, stem from
the fact that synchronous appendiceal and ovarian disease
is common and the overall female preponderance for
PMP [3]. Immunohistochemistry and molecular genetics
have, however, lent strength to the current concept of an
appendiceal origin for the vast majority of PMP in both
men and women [1].
Most cases originate from a minimally invasive mucin-
ous epithelial neoplasm (as mentioned above primarily
appendiceal but ovarian and colonic sources have also
been described), which eventually ruptures and releases
mucinous tumor cells into the peritoneal cavity [4]. These
cells show a high propensity for spread to peritoneal sur-
faces, but almost no lymphatic or hematogenous metasta-
ses [5]. Accumulation and the reproduction of free and
Figure 1. Coronal CT scan. The thin arrows highlight the appendiceal
mucocele. The thick arrows highlight the ascites.
Figure 2. Sagittal view. The arrows highlight the omental cake.
Figure 3. Transverse view. The thin arrows highlight the extensive
omental cake and the thick arrows again point towards the ascites.
ª 2014 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 157
A. Chauhan et al. A rare cause of ascites
implanted tumor cells leads to progressive peritoneal
mucinous tumor and ascites [4]. The disease is character-
ized by diffuse intra-abdominal gelatinous collections
(jelly belly) with mucinous implants on peritoneal sur-
faces and the omentum [4]. The locoregional progression
of the disease (redistribution phenomenon) [6] results in
intestinal failure and malnutrition secondary to raised
intra-abdominal pressure, fistula formation, and infection
[7], hence the associated considerable mortality and mor-
bidity. Ronnett et al. proposed three pathological sub-
types of the condition [8]. DPAM, a low-grade lesion
with a good prognosis; peritoneal mucinous adenocarci-
noma (PMCA), which is histopathologically a high-grade
metastatic adenocarcinoma, usually derived from the
appendix and colon, with a poor prognosis; and interme-
diate type PMP (PMCA-I), which includes lesions that
demonstrate predominantly features of DPAM, but also
contain focal areas of PMCA (intermediate prognosis)
[9]. Other classification systems exist but the one devised
by Ronnett et al. is the most commonly used one.
The imaging and staging modality of choice is abdomi-
nal CT scanning [10], with scalloping and characteristic
patterns of disease on visceral surfaces being almost
pathognomic of PMP. In most cases, the striking feature
is the relative sparing of the small bowel and its mesen-
tery, with the small bowel “compartmentalized” in the
center of the abdomen by a large omental cake [11].
Septa, curvilinear or amorphous calcification, areas of soft
tissue attenuation due to solid elements within mucinous
material and compressed mesentery are seen as the vol-
ume of disease increases [12]. Lee et al. argue that due to
high water content, mucin has a similar appearance to
water on both CT and MR imaging, but when the mucin
produced is thick and proteinaceous then it tends to be
hyperdense compared to water and hyperintense on T1-
and hypointense on T2-weighted images. The role of MR
imaging in PMP is, however, yet to be established [13].
Although anaemia is a common finding, laboratory
studies are of very limited use in diagnosing PMP, with the
definitive diagnosis usually being established at laparotomy
[14]. Tumor markers CEA, CA-19.9, and CA-125 are
raised, the specificity and sensitivity of these markers in
PMP has not been extensively studied and therefore their
diagnostic utility in PMP is likely to be restricted at best.
Baratti et al. however demonstrate a role for these markers
in post-treatment prognostication. They reveal a correla-
tion between a normal preoperative CA-125 with the likeli-
hood of achieving adequate cytoreduction at surgery (a
significant prognostic factor for PMP) and go on to suggest
that an increased baseline CA19.9 is an independent inverse
predictor of progression-free survival after treatment [15].
Tumor markers can be used to monitor response to
treatment and as surveillance tools to look for recurrence.
In the past, this disease was uniformly fatal. Treatment
was essentially restricted to interval debulking with no
realistic prospect of long-term cure [6]. The natural history
of the disease has substantially been altered by Sugarbaker
et al., who in 1994 devised a procedure involving a radical
peritonectomy aimed at removing as much macroscopic
disease (cytoreductive surgery, CRS) as possible. The oper-
ation takes about 10 hours to complete and includes:
Removal of the right hemicolon, spleen, gall bladder,
greater omentum, and lesser omentum
Stripping of the peritoneum from the pelvis and dia-
phragm
Stripping of tumor from the surface of the liver
Removal of the uterus and ovaries in women
Removal of the rectum in some cases.
The surgery is followed by HIPEC to eliminate micro-
scopic and residual disease (http://publications.nice.org.
uk/complete-cytoreduction-for-pseudomyxoma-peritonei-
sugarbaker-technique-ipg56). This remains the best treat-
ment regime in patients medically fit enough. No clear
strategy exists for patients not fit enough to undergo this
complex and aggressive treatment; palliative interval deb-
ulking appears to be the favored option here, however
there may be a role for systemic chemotherapy as well.
Technically a demanding procedure, requiring specialized
equipment, the Sugarbaker procedure is not without rea-
sonable postoperative morbidity and mortality [1], Major
morbidity includes anastomotic leakage, enteric and pan-
creatic fistulation, pneumonia, thromboembolism, and
intra-abdominal abscesses [16]. Morbidity from intraperi-
toneal chemotherapy (mitomycin C), takes the form of
septic sequelae especially neutropenic sepsis [17].
Glehen et al. [18] report a median survival of
156 months, with 5- and 10-year survival of 72% and 55%,
respectively, in 501 PMP patients who had undergone CRS
(complete and incomplete) followed by HIPEC. The major-
ity (~70%) had complete cytoreduction. This uniform treat-
ment approach has shown improved 10-year survival, as
compared with historical controls [19, 20]. Overall, how-
ever, long-term survival rates remain poor with 5 and 10-
year survival rates of 50% and 10–30%, respectively [20–22].
Learning Points
1 PMP is no longer an incurable condition.
2 Once diagnosed, patients should be referred to a spe-
cialist unit early for further management.
3 Although technically curable, the morbidity from this
condition is sizeable and a multidisciplinary approach
with specialist input from the nutrition team is essen-
tial. Regular and thorough monitoring of nutritional
status in patients earmarked for aggressive therapy is
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appropriate, as if intestinal failure (known consequence
of bulky PMP) is suspected parenteral nutrition may be
necessary to optimize preoperative status.
4 In patients deemed not fit for very aggressive treat-
ment, palliative options including limited debulking
and systemic chemotherapy should be considered.
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